As a followup to the recent Senate Finance Committee hearing on drug pricing, Sen. Steve Daines (R-Mont.) has asked chief executives of two drug makers to explain discrepancies in their responses to a question about withholding samples from generic rivals.
Daines raised the issue at the Feb. 26 hearing over concerns about unfair competition and the effect on drug prices. Generic companies need samples to develop copycat medicines and sometimes run tests to show a product is bioequivalent in order to win regulatory approval.
About the Author Reprints
